Stock Events

Stock Events

Omnimmune 

$0.000100
2
+$0.00+0%Thursday 13:30

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.0001
52W Low
0.0001
Volume
169,071
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap75.86B
Moderna Inc. focuses on mRNA-based therapies, directly competing in the immunotherapy space similar to Omnimmune's approach.
BioNTech
BNTX
Mkt Cap24.34B
BioNTech SE develops and commercializes immunotherapies, a direct competitor in the field of personalized medicine like Omnimmune.
Novavax
NVAX
Mkt Cap1.73B
Novavax, Inc. is involved in the development of vaccines that stimulate the immune system, competing in the broader immunotherapy market.
Gilead Sciences
GILD
Mkt Cap179.47B
Gilead Sciences, Inc. offers antiviral drugs and other treatments that enhance immune response, aligning closely with Omnimmune's therapeutic areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals, Inc. is known for its innovations in immunology and biotechnology, making it a significant competitor in immune-focused therapies.
AMGEN
AMGN
Mkt Cap217.9B
Amgen Inc. develops biologic therapies, including immune modulators, which pits it against Omnimmune in the biotech and pharmaceutical sectors.
Pfizer
PFE
Mkt Cap158.45B
Pfizer Inc. has a broad portfolio including immunotherapies and vaccines, competing on multiple fronts with Omnimmune.
Johnson & Johnson
JNJ
Mkt Cap617.01B
Johnson & Johnson engages in the development of immunotherapies and vaccines, overlapping with Omnimmune's market interests.
Astrazeneca
AZN
Mkt Cap243.34B
AstraZeneca PLC has a strong focus on biopharmaceuticals in immunology, making it a competitor in the same therapeutic areas as Omnimmune.
Novartis
NVS
Mkt Cap268B
Novartis AG offers a range of immunomodulatory drugs, directly competing with Omnimmune in the pharmaceutical and biotech industries.

About

Omnimmune Holdings, Inc., through its subsidiary, Omnimmune Corp., operates as a development-stage biotechnology company integrating complementary cancer therapeutic, diagnostic, and prognostic technologies in the United States. The company owns rights for monoclonal antibody technologies. It also intends to develop personalized cancer treatment with the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, which target a hormone called human chorionic gonadotropin. In addition, the company plans to conduct a Phase I trial with its lead candidate anti-human chorionic gonadotropin beta subunit monoclonal antibodies based upon the results of the diagnostic trial. Omnimmune Holdings, Inc. is based in Houston, Texas.
Show More
CEO
Saul Leal
Employees
2
Country
United States
ISIN
US68216A1043

Listings

OTC Link
US
OMMH

0 Comments

Share your thoughts

FAQs

What is Omnimmune stock price today?▼
The current price of OMMH is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Omnimmune stock price performance more closely on the chart.
What is Omnimmune stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Omnimmune stocks are traded under the ticker OMMH.
Is Omnimmune stock price growing?▼
OMMH stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Omnimmune has showed a -0% decrease.
How many employees does Omnimmune have?▼
As of November 1, 2026, the company has 2 employees.
In which sector is Omnimmune located?▼
Omnimmune operates in the Health & Wellness sector.
When did Omnimmune complete a stock split?▼
The last stock split for Omnimmune was on July 1, 2008 with a ratio of 3:1.
Where is Omnimmune headquartered?▼
Omnimmune is headquartered in Houston, United States.